Ameriprise
KROS icon

Ameriprise’s Keros Therapeutics KROS Stock Holding History

Ameriprise’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Sell
102,479
-20,349
-17% -$314K ﹤0.01% 3238
2025
Q4 		$2.5M Buy
122,828
+2,395
+2% +$42K ﹤0.01% 2873
2025
Q3 		$1.91M Buy
120,433
+21,792
+22% +$322K ﹤0.01% 3029
2025
Q2 		$1.32M Buy
+98,641
New +$1.33M ﹤0.01% 3153

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Ameriprise's KROS Position: Q1 2026 in Review

Ameriprise reduced its Keros Therapeutics (KROS) stake by 17% in Q1 2026, selling an estimated $314K and leaving 102,479 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3238.

Ameriprise first reported a position in KROS in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.5M in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Ameriprise held 102,479 shares of Keros Therapeutics worth $1.13M as of Q1 2026.
  • Ameriprise sold 20,349 Keros Therapeutics shares in Q1 2026, an estimated $314K.
  • Keros Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3238 holding.
  • Ameriprise first reported a position in Keros Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Ameriprise's Keros Therapeutics position peaked at $2.5M in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.